Around 50% of high-risk neuroblastomas exhibit MYCN amplification100 which is associated with reduced IFN-I pathway activity and insensitivity to ICB, therefore activating the STING pathway may be beneficial in targeting MYCN amplified neuroblastoma tumours. Here, STING1 is linked to neuroblastoma.